Yanuki
Finance / Earnings
Merck (MRK) reported fourth-quarter earnings that exceeded expectations, fueled by strong demand for its cancer immunotherapy Keytruda and newer products. However, the company's 2026 outlook is tempered by impending patent expirations and i...
Finance / Stocks
Despite strong track records and substantial market caps, Merck, Novo Nordisk, and Pfizer are considered by some analysts to be surprisingly undervalued. This article explores the reasons behind this perception and the potential opportuniti...
Finance / Stock Analysis
Merck (MRK) is navigating a complex landscape of pipeline expansion, tariff pressures, and strategic portfolio diversification. Recent analysis suggests a bullish outlook based on proactive acquisitions and growth in key business segments....
